Insider Selling Y-mAbs Therapeutics, Inc. Insider Sells 65,000 Shares of Stock
YMAB Stock | USD 9.77 0.24 2.40% |
About 67% of Y MAbs' investor base is looking to short. The analysis of the overall investor sentiment regarding Y mAbs Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Y MAbs' historical and current headlines, can help investors time the market. In addition, many technical investors use Y mAbs Therapeutics stock news signals to limit their universe of possible portfolio assets.
YMAB |
Y-mAbs Therapeutics, Inc. insider Thomas Gad sold 65,000 shares of the companys stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of 13.47, for a total value of 875,550.00. Following the sale, the insider now directly owns 97,681 shares in the
Read at thelincolnianonline.com
Y MAbs Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Y MAbs can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Y MAbs Fundamental Analysis
We analyze Y MAbs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Y MAbs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Y MAbs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Y MAbs is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Y mAbs Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Y MAbs stock to make a market-neutral strategy. Peer analysis of Y MAbs could also be used in its relative valuation, which is a method of valuing Y MAbs by comparing valuation metrics with similar companies.
Peers
Y MAbs Related Equities
PASG | Passage Bio | 2.63 | ||||
PCVX | Vaxcyte | 0.69 | ||||
BDTX | Black Diamond | 0.79 | ||||
KRON | Kronos Bio | 1.96 | ||||
BLUE | Bluebird Bio | 2.56 | ||||
DAWN | Day One | 2.66 | ||||
MIRM | Mirum Pharmaceuticals | 3.05 | ||||
RVMD | Revolution Medicines | 3.23 | ||||
MRUS | Merus BV | 4.03 | ||||
ARQT | Arcutis Biotherapeutics | 4.07 | ||||
TVTX | Travere Therapeutics | 4.12 | ||||
SNDX | Syndax Pharmaceuticals | 5.34 | ||||
ERAS | Erasca | 5.40 | ||||
EWTX | Edgewise Therapeutics | 5.54 | ||||
LRMR | Larimar Therapeutics | 6.00 | ||||
GBIO | Generation Bio | 6.30 | ||||
CCCC | C4 Therapeutics | 8.28 | ||||
STRO | Sutro Biopharma | 10.20 | ||||
ZNTL | Zentalis Pharmaceuticals | 10.57 | ||||
MRSN | Mersana Therapeutics | 14.18 |
Complementary Tools for YMAB Stock analysis
When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |